Celcuity Inc. CELC
Super Investor & Insider
1
Fondi che lo detengono
#1266
Rank consenso
1.4%
% dei portafogli
$2.0M
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Polen Capital Management · Polen Capital Management | 0.01% | Add 268.69% | 17,181 | $2.0M |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company’s lead product candidate, gedatolisib, is designed to inhibit the PI3K/AKT/mTOR signaling pathway, which plays a central role in cancer cell growth and survival. Celcuity’s …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees155
TickerCELC
Statistics
Market Cap$4.19B
Revenue (TTM)—
Net Income-$177.0M
Net Margin—
EPS$-3.79
P/E-23.64
P/S—
P/B80.07
EV/EBITDA-23.88
ROE-275.2%
Dividend Yield—
Price$86.66
Data: Twelve Data · Revenue = mcap / P/S